Pill Connect Secures Investment to Enhance Clinical Trials

Pill Connect, a Manchester-based medtech company, has received fresh investment from the GMC Life Sciences Fund By Praetura and NPIF II Praetura Equity Finance, which are part of the Northern Powerhouse Investment Fund II. Pill Connect has developed a digital device that helps pharmaceutical companies track medicine adherence in clinical trials. Its device, which attaches to pill bottles, provides real-time dispensing data to ensure compliance with dosage guidelines. This data is crucial in improving the accuracy of drug efficacy evaluation, thereby reducing delays in obtaining regulatory approvals for new drugs. The company plans to use the funds to expand its team, enhance its device features, and explore new use cases. Pill Connect's technology not only aids clinical trials but also has potential applications for vulnerable populations like dementia patients by providing medication management tools. CEO James Burnstone expressed excitement about this commercial phase, with the device already used in ongoing clinical trials, supported by partnerships with companies like Aardex and Aptar. Investment director Sim Singh-Landa emphasized the impact of the device in enhancing compliance in decentralized trials. Dr. Kath Mackay noted this investment aligns with the goals of supporting the life sciences ecosystem in the region.